在寄生病中开发固体脂质纳米颗粒载荷药物
Sara Nemati1, Mahsa Mottaghi2, Parisa Karami2
1Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Discover nano
|January 4, 2024
概括
固体脂质纳米颗粒 (SLN) 为传统抗寄生虫药物提供了一个有希望的替代品,减少毒性并改善药物输送. 本综述探讨了用于增强抗寄生虫治疗的SLN.
科学领域:
- 纳米医学和药物输送
- 寄生虫学的寄生虫学
- 材料科学 材料科学 材料科学
背景情况:
- 寄生虫感染导致全球范围内的各种疾病和疫情,目前的治疗方法具有显著的毒性和副作用.
- 传统的抗寄生虫药物面临的局限性包括毒性和不良的向传递,需要创新的治疗策略.
- 纳米载体,特别是固体脂质纳米颗粒 (SLN),通过提高药物的疗效和减少不良影响,显示出克服这些局限性的潜力.
研究的目的:
- 审查固体脂质纳米颗粒 (SLN) 的开发和应用,以提供抗寄生虫剂.
- 总结准备方法,表征技术和寄生病中SLN的药物加载策略.
- 突出基于SLN的治疗方法对抗寄生虫感染的最新进展.
主要方法:
- 文献综述侧重于固体脂质纳米颗粒 (SLN) 和它们在寄生病中的使用.
- 分析详细介绍抗寄生虫SLN的制备和表征的研究.
- 对寄生虫感染的药物载荷SLN的最新研究的综合.
主要成果:
- SLN表现出适当的释放率,稳定性和目标传递,使其成为有效的体载体,用于抗寄生虫药物.
- 纳米粒子工程提高了SLN的稳定性和药物载荷能力.
- SLN显示出提供具有抗寄生虫性质的天然产品和合成药物的巨大潜力.
结论:
- 固体脂质纳米颗粒代表了治疗寄生病的可行和先进的药物输送系统,提供了更好的安全性和有效性.
- 在纳米医学中SLN的应用为开发下一代抗寄生虫疗法提供了一个有希望的途径.
- 对SLN配方的进一步研究可以优化对广泛的寄生虫感染的治疗.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


